Site for WUH APOLLO TRIAL: Transcatheter Mitral Valve Replacement with the Medtronic Intrepid TMVR System in patients with severe symptomatic mitral regurgitation APOLLO Trial
Site for Multi-center, global, prospective, randomized, interventional, pre-market trial Subjects will be randomized on 1:1 basis to either TMVR with the Medtronic Intrepid™ TMVRSystem or to conventional mitral valve surgery.Subjects ineligible for randomization may be enrolled through a single-arm trial. Subjectsenrolled in the single-arm cohort will be assigned to TMVR with the Medtronic Intrepid™ TMVR System
Site for WUH TrialNet: NATURAL HISTORY STUDY OF THE DEVELOPMENT OF TYPE 1 DIABETES
Site for The TrialNet Natural History Study of the Development of T1D is divided into Screening and Monitoring stages. Each stage will require separate informed consent for entry. Screening involves testing relatives of individuals with diabetes for the presence of islet autoantibodies. Individuals who have autoantibodies will be enrolled into the Monitoring stage (see Appendix Schedule of Assessments). The study will use a prospective cohort design.The algorithm below shows the flow of participants in the Screening and Monitoring stages. The Screening stage involves measurement of GAD65A, IA-2A, and mIAA, (with a positive result for any of these leading to measurement of ICA and ZnT8A) to determine whether the participant is eligible for the Monitoring stage. As additional diabetes-related autoantibodies are discovered and validated, they may also be included in Screening. Participants will be eligible for Monitoring if they have at least two positive autoantibodies on a Screening sample or at least one positive autoantibody on two separate Screening samples. Participants younger than 18 years old who are negative for all autoantibodies will be offered annual autoantibody rescreening until their 18th birthday. Participants 18 or older with a single positive autoantibody on the first Screening sample but no positive autoantibodies on a confirmatory test will be offered annual rescreening for two years.
Sjogren's Syndrome | NYU Langone Health
NYU Langone rheumatologists diagnose and treat Sjogren’s syndrome, an autoimmune disorder.
Skin & Cancer Unit | NYU Langone Health
NYU Langone’s Skin and Cancer Unit provides expert diagnostic and treatment services for virtually all skin diseases for patients of all ages.
Skin & Cosmetic Conditions | NYU Langone Health
NYU Langone dermatologists and plastic surgeons treat skin and cosmetic conditions in both adults and children.
Skin Autoimmune Disorder Services | NYU Langone Health
NYU Langone dermatologists specialize in treating autoimmune connective tissue diseases of the skin.
Skin-Directed Therapy for Cutaneous T-Cell Lymphoma | NYU Langone Health
NYU Langone doctors use skin-directed therapy, including topical medication, phototherapy, and radiation therapy, for cutaneous T-cell lymphoma.
Skin of Color Services | NYU Langone Health
NYU Langone dermatologists are experts in diagnosing and treating a wide range of conditions that affect skin of color.
Skull Base Tumors | NYU Langone Health
NYU Langone doctors treat people who have skull base tumors with minimally invasive surgery, targeted radiation therapy, or medication.
Sleep & Breathing Services for Children | NYU Langone Health
Doctors at Hassenfeld Children’s Hospital at NYU Langone offer advanced sleep and breathing services to manage a child’s sleep apnea.